Completed

CP-547,632 and Chemotherapy Combination for Advanced Non-Small Cell Lung Cancer Treatment

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Lung Diseases+4

+ Lung Neoplasms

+ Neoplasms

Over 18 Years
+5 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1 & 2
Interventional
Study Start: May 2002
See protocol details

Summary

Principal SponsorPfizer
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2002

Actual date on which the first participant was enrolled.

This study explores the effectiveness of an oral medication, CP-547,632, in combination with standard chemotherapy for treating advanced stage non-small cell lung cancer. The medication, CP-547,632, is a type of drug known as a tyrosine kinase inhibitor, specifically targeting VEGFR-2. The goal is to determine if this combination therapy offers improved outcomes compared to chemotherapy alone for individuals with this form of lung cancer. Participants in this study receive either the combination of CP-547,632 and chemotherapy (carboplatin and paclitaxel), or just the chemotherapy. The study's primary focus is to evaluate if the addition of CP-547,632 to chemotherapy leads to better results. However, it's important to note that the study was discontinued due to statistical estimates suggesting a low likelihood of positive outcomes if it continued to the next stage.

Official TitleA Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.
NCT00074854
Principal SponsorPfizer
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

87 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Lung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic Neoplasms

Criteria

2 inclusion criteria required to participate
Histologically or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc).
Bidimensionally measurable disease >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan.
3 exclusion criteria prevent from participating
No tumors in close proximity to major veins or arteries.
No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease.
No evidence or history brain metastases.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 20 locations

Suspended

Pfizer Investigational Site

Greenbrae, United StatesOpen Pfizer Investigational Site in Google Maps
Suspended

Pfizer Investigational Site

San Mateo, United States
Suspended

Pfizer Investigational Site

San Pablo, United States
Suspended

Pfizer Investigational Site

Tampa, United States
Completed20 Study Centers